FORXIGA® (dapagliflozin)

FORXIGA® is a highly selective SGLT2 inhibitor for type 2 diabetes mellitus, with 4-year safety and efficacy data, that removes glucose and its associated calories via the kidney.1

FORXIGA®(dapagliflozin) Therapeutic Indications and Posology

Indications

FORXIGA® is indicated in adults aged 18 years and older with type 2 diabetes to improve glycaemic control as:1

Monotherapy
  • When diet and exercise alone do not provide adequate glycaemic control in patients for whom the use of metformin is considered inappropriate due to intolerance1
Add-on combination therapy
  • In combination with other glucose-lowering medicinal products including insulin when these, together with diet and exercise, do not provide adequate glycaemic control1

Posology

The recommended dose is 10 mg* FORXIGA® once daily for monotherapy and add-on combination therapy with other glucose-lowering medicinal products including insulin.1

*In patients with severe hepatic impairment, a starting dose of 5 mg is recommended. If well tolerated, the dose may be increased to 10 mg.1
FORXIGA® is not recommended for use in patients with estimated glomerular filtration rate [eGFR] < 60 ml/min/1.73 m2.1
The use of FORXIGA® with pioglitazone is not recommended.1